Trega Biosciences, Inc.

Paul Omholt

Ronald R Tuttle

Beverly E Girten

Richard Allen Houghten

Mark J Suto

Amaresh Basu

Costas C Loullis

Patricia A Weber

Ali Andalibi

Patrick Fagan

The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.

Method for reducing the severity of gastro-intestinal damage

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

Cytokine regulatory agents and methods of use in pathologies and

Growing community of inventors

San Diego, CA, United States of America

Paul Omholt